Business Wire

bitFlyer Makes Cryptocurrency Trading Even Easier with Launch of bitFlyer App

21.10.2019 08:00:00 EEST | Business Wire | Press release

Share

Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin (LTC), Bitcoin Cash (BCH), Ethereum Classic (ETC), Monacoin (MONA) and Lisk (LSK).1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191020005009/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

bitFlyer app iOS

The bitFlyer app will make it even easier for users to buy and sell, whilst still adhering to the same robust KYC and verification standards as the bitFlyer website.

Since 2014, bitFlyer has been trusted by millions across the globe as the most secure platform to easily buy and sell cryptocurrencies, and remains the only exchange licensed to operate across the US, Japan and Europe combined. This app launch is the latest development in a major growth strategy by the European and US businesses, to match what is already available to millions of bitFlyer Japan customers, where bitFlyer is recognised as a household name and one of the longest-standing cryptocurrency exchanges.

Yuzo Kano, bitFlyer founder and CEO of bitFlyer USA, said: “With the new bitFlyer apps, we are bringing the reliability, security and experience of Japan's market leader to our European and American customers, closing the gap between our service offerings and creating a truly global and regulated exchange product.”

Andy Bryant, Co-head and COO at bitFlyer Europe, said: “With our Buy/Sell platform, we strived to create a simpler, faster and even more transparent experience where everyone can buy cryptocurrencies in just a few minutes and from a reputable source. Now with the bitFlyer app, this is even more convenient for users.

We are staying true to our mission of making the world simpler with blockchain, by making the transparency, security and simplicity of our robust trading platforms available via a quick, single app download.”

Buy instantly and securely

The bitFlyer app was created with users in mind, making it even easier for those who prefer navigating from a smartphone to buy and sell cryptocurrencies. Current bitFlyer users can log on to the app with their existing account details, while new traders can register by using an email address, and inputting the relevant information for KYC procedures to deposit and begin trading.

Other features of the bitFlyer app include:

● Users are shown real-time price data, notified about the latest market movements and given access to the latest cryptocurrency news without leaving the app, encouraging users to always stay on top of the market and make informed decisions

● Users can clearly follow their position, making it even easier to keep track of profit and loss (PnL), view trade history and seamlessly visualise their portfolio

● Users can now simply scan a QR code to send and receive virtual currencies with bitFlyer

● From October 21st to October 27th, new customers downloading the bitFlyer app and registering a new verified account will receive €10 (or $10 if based in the US) in BTC without any deposit required.

Key features:

● Buy Bitcoin, Ethereum, Litecoin and more in just a few taps using USD, EUR, or JPY 2

● See real-time price data and get notified about market movements

● Added news functionality allows users to access the latest industry news without leaving the app

bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.

bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. It believes that standards and regulations are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised bitcoin as legal tender.

The company continues to build out its product portfolio in line with its vision to break down barriers of entry that many face while accessing cryptocurrency. bitFlyer Japan already offers a wide range of products, and the addition of new Apps in the US and EU is the beginning of the brand’s ambition to expand access to cryptocurrency on a global scale.

ENDS

About bitFlyer EUROPE S.A.

bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell cryptocurrencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/

About bitFlyer USA, Inc.

bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell cryptocurrencies. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York as a holder of the New York Bitlicense. bitFlyer USA, Inc., site: https://bitflyer.com/en-us/

1MONA and LSK available in Europe and Japan only.

2 Depending on jurisdiction

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lauren Armour
Tyto PR
07826 557 326

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye